Hybridoma (Monoclonal Antibody) Core
杂交瘤(单克隆抗体)核心
基本信息
- 批准号:7706296
- 负责人:
- 金额:$ 36.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-03-01 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAntigensAntitoxinsAntiviral AgentsAscitesAutoimmunityBacillus anthracisBiologicalBioterrorismCancer CenterCellsCloningCommitCommunicable DiseasesCountryDecision MakingDiphtheria ToxinE proteinEnterotoxinsEpidemicFacultyFiberFreezingFundingGenerationsGoalsHumanHuman ResourcesHybridomasImmune SeraImmunityImmunizationImmunoglobulin Somatic HypermutationIn VitroIndividualInstitutionLearningLiquid substanceMalignant NeoplasmsMediatingMedicineMonoclonal AntibodiesMorbidity - disease rateMusNumbersPersonsProcessProductionProductivityPropertyProtein SubunitsProteinsPublic HealthRateRattusResearch PersonnelSCID MiceScreening procedureSerumStaphylococcus aureusTechnologyTestingTetanusTherapeuticTherapeutic antibodiesTimeToxinTrainingUnited StatesViralVirusWest Nile virusWorkactivation-induced cytidine deaminaseanthrax lethal factoranthrax toxincollegeedema factorflasksin vivomembermortalityneutralizing antibodypassive antibodiespressureprophylacticsizetissue culturevirus envelope
项目摘要
Passive antibody administration is the only strategy available for conferring immediate immunity to
individuals exposed to biological weapons. Furthermore, toxin-specific antibodies are toxin neutralizing
agents par excellence and currently constitute the only means of neutralizing toxins in the human host. The
efficacy of antitoxin sera in human therapy is known since the 1890s when Behring and Kitasato developed
antisera to tetanus and diphtheria toxins and demonstrated their prophylactic and therapeutic properties.
However, despite a century of immunological study we know relatively little about what antibody properties
are important for antitoxin efficacy and the mechanisms involved in toxin neutralization are largely
conjecture. This application is focused on the generation of antibodies to four toxins: B. anthracis toxins
(protective antigen, lethal factor, and edema factor protein subunits) and Staphylococcus aureus enterotoxin
with the goal of generating therapeutic antibodies to protect against biological attack with these agents. In
addition we will generate neutralizing antibodies to West Nile Virus (WNV). The United States is currently in
the midst of an unfolding WNV epidemic and there has been some concern that this agent was deliberately
introduced into this country in an act of bioterrorism. While this is unlikely, the morbidity and mortality
associated with WNV remain a significant public health concern. Four Specific Aims are proposed: 1) To
generate neutralizing (murine and human) mononclonal antibodies to anthrax toxin protein components, S.
aureus enterotroxin, and WNV envelope (E) protein; 2) To identify the antibody attributes necessary for
optimal toxin and viral neutralizing activity; 3) To generate very high affinity derivatives of neutralizing
antitoxin and antiviral mAbs by increasing the rate of somatic hypermutation in selected hybridomas through
expression of activation induced deaminase (AID); 4) To identify the mechanism(s) of antibody-mediated
toxin and virus neutralization.
被动抗体接种是唯一可用于即时免疫的策略。
接触生物武器的个人。此外,毒素特异性抗体可以中和毒素。
药物是卓越的,目前构成了人体内中和毒素的唯一手段。这个
自19世纪90年代Behring和Kitasato发明以来,抗毒素血清在人类治疗中的有效性就已为人所知。
破伤风和白喉毒素的抗血清,并展示了它们的预防和治疗特性。
然而,尽管进行了一个世纪的免疫学研究,我们对抗体的特性知之甚少。
对于抗毒素的效果很重要,而中和毒素的机制在很大程度上
猜想。这项应用的重点是产生四种毒素的抗体:炭疽杆菌毒素
(保护性抗原、致死因子和水肿因子蛋白亚基)和金黄色葡萄球菌肠毒素
目的是产生治疗性抗体,以防止这些制剂的生物攻击。在……里面
此外,我们还将产生西尼罗河病毒(WNV)的中和抗体。美国目前正处于
在西尼罗河病毒流行期间,有人担心这种病毒是故意
在一次生物恐怖主义行动中被带入这个国家。虽然这不太可能,但发病率和死亡率
与西尼罗河病毒相关的疾病仍然是一个重大的公共卫生问题。提出了四个具体目标:1)
产生中和(鼠和人)抗炭疽毒素蛋白组分的单抗,S.
金黄色葡萄球菌肠毒素和西尼罗河病毒包膜(E)蛋白;2)鉴定所需抗体属性
最佳的毒素和病毒中和活性;3)产生非常高亲和力的中和衍生物
抗毒素和抗病毒单抗通过以下途径提高杂交瘤细胞的体细胞高突变率
活化诱导脱氨酶的表达;4)确定抗体介导的机制(S)
毒素和病毒中和。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATTHEW D SCHARFF其他文献
MATTHEW D SCHARFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATTHEW D SCHARFF', 18)}}的其他基金
Mismatch repair in V region mutation and isotype switching
V区突变和同种型转换中的错配修复
- 批准号:
8403693 - 财政年份:2003
- 资助金额:
$ 36.01万 - 项目类别:
Mismatch repair in V region mutation and isotype switching
V区突变和同种型转换中的错配修复
- 批准号:
7758277 - 财政年份:2003
- 资助金额:
$ 36.01万 - 项目类别:
Mismatch Repair in V region mutation and isotype switch
V区突变和同种型转换中的错配修复
- 批准号:
7076248 - 财政年份:2003
- 资助金额:
$ 36.01万 - 项目类别:
Mismatch repair in V region mutation and isotype switching
V区突变和同种型转换中的错配修复
- 批准号:
9132482 - 财政年份:2003
- 资助金额:
$ 36.01万 - 项目类别:
Mismatch repair in V region mutation and isotype switching
V区突变和同种型转换中的错配修复
- 批准号:
9109534 - 财政年份:2003
- 资助金额:
$ 36.01万 - 项目类别:
Mismatch repair in V region mutation and isotype switching
V区突变和同种型转换中的错配修复
- 批准号:
7579404 - 财政年份:2003
- 资助金额:
$ 36.01万 - 项目类别:
Mismatch Repair in V region mutation and isotype switch
V区突变和同种型转换的错配修复
- 批准号:
6925507 - 财政年份:2003
- 资助金额:
$ 36.01万 - 项目类别:
Mismatch repair in V region mutation and isotype switching
V区突变和同种型转换中的错配修复
- 批准号:
8900937 - 财政年份:2003
- 资助金额:
$ 36.01万 - 项目类别:
相似海外基金
Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
使用病毒样颗粒缀合物免疫和高通量选择的合理引导的针对碳水化合物抗原的单克隆抗体的发现平台
- 批准号:
10574738 - 财政年份:2023
- 资助金额:
$ 36.01万 - 项目类别:
Assessing the role of liver stage antigens-specific antibodies against Plasmodium falciparum liver stage infection
评估肝期抗原特异性抗体对抗恶性疟原虫肝期感染的作用
- 批准号:
10392870 - 财政年份:2021
- 资助金额:
$ 36.01万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
10092930 - 财政年份:2020
- 资助金额:
$ 36.01万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
9896170 - 财政年份:2020
- 资助金额:
$ 36.01万 - 项目类别:
Interrogation of cell surface antigens on B lineage cells using structurally unique variable lymphocyte receptor antibodies of the evolutionarily distant sea lamprey
使用进化遥远的海七鳃鳗结构独特的可变淋巴细胞受体抗体询问 B 谱系细胞上的细胞表面抗原
- 批准号:
433456 - 财政年份:2020
- 资助金额:
$ 36.01万 - 项目类别:
Operating Grants
Investigations of interactions between various natural antibodies and food-derived antigens
研究各种天然抗体与食物源性抗原之间的相互作用
- 批准号:
19K15765 - 财政年份:2019
- 资助金额:
$ 36.01万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying Kawasaki Disease-Specific Antibodies and Antigens
识别川崎病特异性抗体和抗原
- 批准号:
9932769 - 财政年份:2018
- 资助金额:
$ 36.01万 - 项目类别:
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
BB/P504713/1 - 财政年份:2017
- 资助金额:
$ 36.01万 - 项目类别:
Training Grant
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
1932904 - 财政年份:2017
- 资助金额:
$ 36.01万 - 项目类别:
Studentship
SBIR Phase II: Automated Design Methods of Antibodies Directed to Protein and Carbohydrate Antigens
SBIR II 期:针对蛋白质和碳水化合物抗原的抗体的自动化设计方法
- 批准号:
1632399 - 财政年份:2016
- 资助金额:
$ 36.01万 - 项目类别:
Standard Grant














{{item.name}}会员




